Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells
- 1 August 2010
- journal article
- Published by Microbiology Society in Journal of General Virology
- Vol. 91 (8) , 1959-1970
Abstract
In viral myocarditis, adeno- and enteroviruses have most commonly been implicated as causes of infection. Both viruses require the human coxsackie-adenovirus receptor (CAR) to infect the myocardium. Due to its crucial role for viral entry, CAR-downregulation may lead to novel approaches for treatment for viral myocarditis. In this study, we report on pharmaceutical drug influences on CAR levels in human umbilical vein endothelial cells (HUVEC) and cervical carcinoma cells (HeLa) detected by immunoblotting, quantitative real time-PCR and cellular susceptibility to the cardiotropic coxsackie-B3 virus strain Nancy (CVB3). Our results indicate, for the first time, a dose-dependent CAR mRNA and protein downregulation upon Valsartan and Bosentan treatment. Most interestingly, drug-induced CAR diminution significantly reduced the viral load in CVB3-infected HUVEC. In order to assess the regulatory effects of both drugs in detail, we knocked down their protein targets, the G-protein coupled receptors angiotensin-II type-1 receptor (AT1R) and endothelin-1 type-A and -B receptors (ETAR/ETBR) in HUVEC. Receptor-specific gene silencing indicates that CAR gene expression is regulated by agonistic and antagonistic binding to ETBR, but not ETAR. In addition, neither stimulation nor inhibition of AT1R seemed to be involved in CAR gene regulatory processes. Our study indicates that Valsartan and Bosentan protected human endothelial cells from CVB3-infection. Therefore, besides their well-known anti-hypertensive effects these drugs may also protect the myocardium and other tissues from coxsackie- and adenoviral infection.Keywords
This publication has 36 references indexed in Scilit:
- Prevention of Cardiac Dysfunction in Acute Coxsackievirus B3 Cardiomyopathy by Inducible Expression of a Soluble Coxsackievirus-Adenovirus ReceptorCirculation, 2009
- Dynamin- and Lipid Raft-Dependent Entry of Decay-Accelerating Factor (DAF)-Binding and Non-DAF-Binding Coxsackieviruses into Nonpolarized CellsJournal of Virology, 2009
- Tissue-Specific Deletion of the Coxsackievirus and Adenovirus Receptor Protects Mice from Virus-Induced Pancreatitis and MyocarditisCell Host & Microbe, 2009
- The tight junction protein CAR regulates cardiac conduction and cell–cell communicationJournal of Experimental Medicine, 2008
- Acute viral myocarditisEuropean Heart Journal, 2008
- Coxsackievirus Entry across Epithelial Tight Junctions Requires Occludin and the Small GTPases Rab34 and Rab5Cell Host & Microbe, 2007
- Enhanced Cellular Receptor Usage by a Bioselected Variant of Coxsackievirus A21Journal of Virology, 2004
- 17β -Estradiol regulates the expression of endothelin receptor type B in the heartBritish Journal of Pharmacology, 2003
- DETECTION OF COXSACKIE-B-VIRUS-SPECIFIC RNA SEQUENCES IN MYOCARDIAL BIOPSY SAMPLES FROM PATIENTS WITH MYOCARDITIS AND DILATED CARDIOMYOPATHYThe Lancet, 1986
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970